A new artificial intelligence (AI) test can identify which men with prostate cancer will benefit most from the life-extending ...

New treatment combinations are transforming genitourinary cancer care, improving survival and quality of life while ...

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. April Rose discussing a ctDNA–directed phase II study of carboplatin in patients with ...

Oncology specialists from UC San Francisco will present new clinical research findings and cutting-edge treatment strategies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ...

A new AI test can detect which men with high-risk prostate cancer could benefit from a life-extending drug. The technology ...

The test, developed by Artera, uses AI to pick up features invisible to the human eye on images of tumour samples.

The FDA approved the poly ADP ribose polymerase (PARP) inhibitor in June 2023 in combination with enzalutamide for men with ...

At that point, additional blood and urine tests can spot biomarkers that may give a better indication if cancer is present, says Michael S. Leapman, M.D., a urologic oncologist at Yale Medicine. “They ...

Prostate cancer is the most common cancer affecting American men other than skin cancer and the second leading cause of male ...